The biopharmaceutical company manufactures medicines for Alzheimer's, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.
Company Info
| CEO | Giovanni Caforio |
| CEO Title | Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New York, NY |
| Website | www.bms.com |
| Years on Fortune 500 List | 23 |
| Employees | 25,000 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $19,427 |
| Profits ($M) | $4,457 |
| Assets ($M) | $33,707 |
| Total Stockholder Equity ($M) | $16,177 |
| Market Value — as of March 31, 2017 ($M) | $89,591 |
Profit Ratios
| Profit as % of Revenues | 22.9% |
| Profits as % of Assets | 13.2% |
| Profits as % of Stockholder Equity | 27.6% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 265 |
| EPS % Change (from 2015) | 184.9% |
| EPS % Change (5 year annual rate) | 4.2% |
| EPS % Change (10 year annual rate) | 12.6% |
Total Return
| Total Return to Investors (2016) | -13% |
| Total Return to Investors (5 year, annualized) | 14% |
| Total Return to Investors (10 year, annualized) | 12.7% |
